Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
HARMONi-7
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- NCT06767514 ↗
- Recruiting
- Summit Therapeutics
- Deep
We haven't built an HCP commentary report on HARMONi-7 (ivonescimab in first-line metastatic NSCLC with high PD-L1 expression) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HARMONi-7 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 18 | |
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ivonescimab Injection; Pembrolizumab Injection
- Arms
- Arm A - Ivonescimab · Experimental
- Arm B - Pembrolizumab · Active comparator
- Enrollment
- 780 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Progression free survival (PFS)
- Sponsor
- Summit Therapeutics
- Start
- Feb 27, 2025
- Primary completion
- Apr 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06767514 · updated Sep 18, 2026